TORONTO -- (MARKET WIRE) -- November 09, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has been granted a new Australian Patent by IP Australia’s Patent Office titled “Pharmaceutical Compositions for Buccal and Pulmonary Application.” The patent covers claims to the composition, processes, and methodologies for the delivery of macromolecules via the buccal cavity of the mouth.
